文献速递泌尿男性生殖肿瘤

阿维鲁单抗联合阿昔替尼一线治疗晚期透明细胞肾细胞癌的初步结果(JAVELIN Renal 100):一项开放标签、剂量探索与剂量扩展的1b期试验

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
PubMed 文献 · Lancet Oncol · 2018-03-09

JAVELIN Renal 100是一项开放标签、多中心、剂量探索与剂量扩展的1b期研究,纳入55例未经系统治疗的晚期透明细胞肾细胞癌患者,评估阿维鲁单抗联合阿昔替尼的剂量限制性毒性、安全性和抗肿瘤活性。结果显示联合方案的最大耐受剂量为阿维鲁单抗10 mg/kg每2周联合阿昔替尼5 mg每日两次,确认客观缓解率为58%(95% CI 44-71),安全性总体可控。

要点

  • 联合方案最大耐受剂量为阿维鲁单抗10 mg/kg每2周联合阿昔替尼5 mg每日两次。
  • 全部55例患者确认客观缓解率为58%(95% CI 44-71)。
  • 3级及以上治疗相关不良事件发生率为58%,最常见为高血压(29%)。

核心结论

  • 在未经治疗的晚期透明细胞肾细胞癌患者中,阿维鲁单抗联合阿昔替尼的安全性总体可控,初步抗肿瘤活性令人鼓舞。

研究设计与样本

  • JAVELIN Renal 100为正在进行的开放标签、多中心、剂量探索与剂量扩展的1b期研究,在美国、英国和日本14个中心开展。
  • 研究纳入55例未经系统治疗的晚期透明细胞肾细胞癌患者,剂量探索阶段6例,剂量扩展阶段49例。
  • 主要终点为阿维鲁单抗联合阿昔替尼治疗前4周(两个周期)内的剂量限制性毒性。

主要发现

  • 剂量探索阶段6例患者中报告1例由阿昔替尼引起的3级蛋白尿剂量限制性毒性。
  • 截至2017年4月13日,剂量探索阶段6例中6例(100%,95% CI 54-100)确认客观缓解,剂量扩展阶段49例中26例(53%,95% CI 38-68)确认客观缓解,全部55例中32例(58%,95% CI 44-71)确认客观缓解。
  • 55例中32例(58%)发生3级及以上治疗相关不良事件,最常见为高血压16例(29%),丙氨酸氨基转移酶升高、淀粉酶升高、脂肪酶升高和掌跖红斑感觉异常综合征各4例(7%)。
  • 55例中6例(11%)在数据截止前死亡,其中5例(9%)死于疾病进展,1例(2%)死于治疗相关自身免疫性心肌炎。

关键数值与推荐

  • 联合方案的最大耐受剂量为阿维鲁单抗10 mg/kg每2周联合阿昔替尼5 mg每日两次。

临床怎么用

  • 该联合方案的初步安全性和抗肿瘤活性数据支持进一步开展3期试验,比较阿维鲁单抗联合阿昔替尼与舒尼替尼单药治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The combination of an immune checkpoint inhibitor and a VEGF pathway inhibitor to treat patients with advanced renal-cell carcinoma might increase the clinical benefit of these drugs compared with their use alone. Here, we report preliminary results for the combination of avelumab, an IgG1 monoclonal antibody against the programmed cell death protein ligand PD-L1, and axitinib, a VEGF receptor inhibitor approved for second-line treatment of advanced renal-cell carcinoma, in treatment-naive patients with advanced renal-cell carcinoma. METHODS: The JAVELIN Renal 100 study is an ongoing open-label, multicentre, dose-finding, and dose-expansion, phase 1b study, done in 14 centres in the USA, UK, and Japan. Eligible patients were aged 18 years or older (≥20 years in Japan) and had histologically or cytologically confirmed advanced renal-cell carcinoma with clear-cell component, life expectancy of at least 3 months, an Eastern Cooperative Oncology Group performance status of 1 or less, received no previous systemic treatment for advanced renal cell carcinoma, and had a resected primary tumour. Patients enrolled into the dose-finding phase received 5 mg axitinib orally twice daily for 7 days, followed by combination therapy with 10 mg/kg avelumab intravenously every 2 weeks and 5 mg axitinib orally twice daily. Based on the pharmacokinetic data from the dose-finding phase, ten additional patients were enrolled into the dose-expansion phase and assigned to this regimen. The other patients in the dose-expansion phase started taking combination therapy directly. The primary endpoint was dose-limiting toxicities in the first 4 weeks (two cycles) of treatment with avelumab plus axitinib. Safety and antitumour activity analyses were done in all patients who received at least one dose of avelumab or axitinib. This trial is registered with ClinicalTrials.gov, number NCT02493751. FINDINGS: Between Oct 30, 2015, and Sept 30, 2016, we enrolled six patients into the dose-finding phase and 49 into the dose-expansion phase of the study. One dose-limiting toxicity of grade 3 proteinuria due to axitinib was reported among the six patients treated during the dose-finding phase. At the cutoff date (April 13, 2017), six (100%, 95% CI 54-100) of six patients in the dose-finding phase and 26 (53%, 38-68) of 49 patients in the dose-expansion phase had confirmed objective responses (32 [58%, 44-71] of all 55 patients). 32 (58%) of 55 patients had grade 3 or worse treatment-related adverse events, the most frequent being hypertension in 16 (29%) patients and increased concentrations of alanine aminotransferase, amylase, and lipase, and palmar-plantar erythrodysaesthesia syndrome in four (7%) patients each. Six (11%) of 55 patients died before data cutoff, five (9%) due to disease progression and one (2%) due to treatment-related autoimmune myocarditis. At the end of the dose-finding phase, the maximum tolerated dose established for the combination was avelumab 10 mg/kg every 2 weeks and axitinib 5 mg twice daily. INTERPRETATION: The safety profile of the combination avelumab plus axitinib in treatment-naive patients with advanced renal-cell carcinoma seemed to be manageable and consistent with that of each drug alone, and the preliminary data on antitumour activity are encouraging. A phase 3 trial is assessing avelumab and axitinib compared with sunitinib monotherapy. FUNDING: Pfizer and Merck.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Choueiri TK, Larkin J, Oya M, et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol. 2018. PMID: 29530667. doi:10.1016/S1470-2045(18)30107-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。